Teva Pharmaceuticals USA, Inc recalls Octreotide Acetate for…
Teva Pharmaceuticals USA, Inc recalls Octreotide Acetate for Injectable Suspension
- Published
- 13 May 2026
- Units affected
- 2,200 kits
- Agency
- FDA
- Country
- United States
The hazard
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1¿ 19-gauge safety injection needle, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 69300 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054. NDC Kit Carton: 0480-9262-08; Vial Label: 0480-9260-01; Tray Label: 0480-9262-08; Diluent Label: 0480-9263-21.
- Brand / company
- Teva Pharmaceuticals USA, Inc
- Codes / lots
- Lot: 45011002, Exp. 03/31/2027
- Distribution
- Nationwide in the USA
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 13 May 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.